RESUMEN
We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012. The highest susceptibility (82%) was found for trimethoprim-sulfamethoxazole. Eighty-one and 63% of all BCC strains were susceptible to ceftazidime-avibactam and ceftolozane-tazobactam, respectively. For temocillin, ceftazidime, piperacillin-tazobactam, and meropenem, at least 50% of the strains were susceptible. B. stabilis seems to be more resistant than other BCC species.
Asunto(s)
Compuestos de Azabiciclo/farmacología , Complejo Burkholderia cepacia/efectos de los fármacos , Ceftazidima/farmacología , Cefalosporinas/farmacología , Fibrosis Quística/microbiología , Tazobactam/farmacocinética , Antibacterianos/farmacología , Complejo Burkholderia cepacia/aislamiento & purificación , Combinación de Medicamentos , Humanos , Pruebas de Sensibilidad Microbiana , Sulfametoxazol/farmacología , Tazobactam/farmacología , Trimetoprim/farmacologíaRESUMEN
Desulfovibrio species are anaerobic Gram-negative bacilli that make up part of the human gastrointestinal and vaginal flora. Infection with these bacteria is usually secondary to an intra-abdominal source. Identification of these bacteria is possible using available contemporary methods. We report the first case of Desulfovibrio desulfuricans bacteraemia identified using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).